TGFβ blockade in pancreatic cancer enhances sensitivity to combination chemotherapy

ABSTRACT: We evaluated the TGFβ blocking antibody NIS793 in combination with either gemcitabine/n(ab)-paclitaxel or FOLFIRINOX chemotherapy in orthotopic pancreatic cancer. Blockade of TGFβ with chemotherapy reduced tumor burden in poorly immunogenic pancreatic cancer, without affecting the metastatic rate of cancer cells. TGFβ blockade decreased total aSMA+ fibroblasts but had minimal effect on fibroblast heterogeneity.

ORGANISM(S): Mus musculus

PROVIDER: GSE224688 | GEO | 2023/04/23

REPOSITORIES: GEO